Malaria is one of the ancient diseases of humanity. Its historical records can be traced back as early as 2700 BC. By the early 1800s, malaria had become a global scourge, afflicting people across the world (Garcia, 2010). Despite scientific and medicinal advancements, malaria is still endemic in over 90 countries, and around 2 billion people are at risk of developing this infection annually (Finnigan, 2023). In the malaria hotspots, it is one of the leading causes of mortality, causing more than 1 million deaths worldwide (Pradines and Robert, 2019).

Malaria is a parasitic infection transmitted to humans by the Anopheles mosquito. When a mosquito bites a human, the parasite responsible for causing malaria is transmitted to the human body. Plasmodium exists in different forms, but only Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae are considered infectious. Among them, P. falciparum causes the most severe disease (Talapko et al., 2019). Malaria symptoms include headache, fever, myalgia, vomiting, and diarrhea. A severe infection can result in life-threatening conditions such as encephalopathy, high-grade fever, and gastroenteritis (Bartoloni and Zammarchi, 2012).

In endemic areas, malaria significantly impacts not only the health of individuals but also their socioeconomic profile. Due to poor living conditions and nutrition status, malaria disproportionately affects impoverished communities, exacerbating the challenges faced by vulnerable social groups (Suh, Kain, and Keystone, 2004). Malaria stands as one of humanity’s most fatal afflictions. The horrors unleashed by this ancient disease persist to the present day. Unfortunately, an effective and potent cure for the infection continues to elude us. The challenges span from complexities of early detection of malaria to obstacles to formulating a suitable remedial strategy, collectively presenting a formidable hurdle in its treatment.

Quinine was the first drug for malaria treatment (Weinke et al., 1992). However, with advancements in medicine, treatment options have also evolved. Currently, chloroquine, artemisinin, proguanil, primaquine, mefloquine, and sulfonamides are used to manage malaria (Gilles and Warrell, 1996). However, there is still no empirical drug for it, as these drugs are plagued by resistance and undesirable side effects (Castelli, Tomasoni, and Matteelli, 2012).

Furthermore, homology modeling and molecular dynamics simulations provide valuable insights into P. falciparum chloroquine resistance transporter (PfCRTs) and its interactions with chloroquine (Patel and Roy, 2021). In vitro assays reveal increased IC₅₀ (a measure of potency) values for mefloquine, suggesting diminished parasite susceptibility. Moreover, the concurrent emergence of resistance to artesunate, coupled with mefloquine resistance, underscores the urgent requirement for alternative approaches to malaria treatment (Rogers et al., 2009b).

For centuries, natural products have been utilized in the treatment of various conditions. This is particularly true for malaria because many anti-malaria drugs are derived from plants, including quinine and artemisinin, which are crucial in malaria control (Kingston and Cassera, 2022). However, the reduced effectiveness of the old therapies due to various reasons including the emergence of resistance in the parasite necessitates the search for newer agents to treat malaria. This article aims to review natural remedies that can be used to treat malaria including the resistant strains while emphasizing the challenges faced by the empirical class of drugs.

According to the World Health Organization’s annual report on malaria, there were more than 240 million malaria cases worldwide. From 2000 to 2021, around 2 billion people were estimated to have suffered from the infection. However, The number of total malaria cases globally increased in 2021, from 245 million in 2020 to 247 million in 2021 (WHO, 2023a; 2022). Most cases are concentrated in the African region (95%), with around 2% in the Southeast Asian region. Approximately 29 countries accounted for 96% of malarial deaths (Figures 1,2; Table 1).

A significant burden of malaria cases is shared by four countries, namely, Nigeria (27%), the Democratic Republic of Congo (12%), Uganda (5%), and Mozambique (4%) (Commission, 2023). Similarly, around 96% of deaths due to malaria occurred in four countries, i.e., Nigeria, the Democratic Republic of Congo, Niger, and the United Republic of Tanzania (WHO, 2023a). According to the WHO, more than 94% of malaria cases (233 million) and 95% of deaths occurred in the African region (Organization, 2023).

However, the epidemiology of malaria in India is distinct due to several features of the Plasmodium parasites, Anopheles vectors, ecoepidemiological aspects conducive to disease transmission, and susceptible humans living in rural and forested areas (Khan MuhammadImran et al, 2023). Notably, in 2021, India accounted for 79% of malaria cases and about 82.4% of all malaria deaths in the South-East Asia Region (Organization, 2022).

Lastly, a systematic review for finding out the prevalence of malaria (from 2001 to 2021) estimated pooled malaria prevalence in Pakistan to be 23.3%, with P. vivax, P. falciparum, and mixed infection rates of 79.13%, 16.29%, and 3.98%, respectively. Moreover, the analysis marked Karachi as the hotspot for malaria with a prevalence rate of 99.79% (Khan Nikhat et al., 2023). This data suggests that malaria is still endemic in most parts of the world. Although the infection rates have decreased over the years, it remains one of the most challenging health problems faced by the global south.

The life cycle of Plasmodium involves humans and mosquitoes, where the human body acts as a site for asexual reproduction, while mosquitoes are involved in the sexual stage of their lifecycle (Figure 3). Mosquitoes serve as vectors and transmit Plasmodium to humans, where it causes malaria (Giribaldi et al., 2015). Plasmodium is transmitted to humans by the female Anopheles mosquito. There are more than 450 species of Anopheles, but about 68 are involved in the transmission of the disease (Giribaldi et al., 2015).

Once it bites a human, the sporozoite form of the parasite is transmitted to the host.

The sporozoite form circulates via the bloodstream and resides in the liver, leading to malaria infection (Menard, 2005). The sporozoites undergo asexual reproduction, resulting in merozoites. This stage is categorized as the “liver stage” with no clinical symptoms. In the case of P. falciparum and P. malariae, the merozoites are released into the bloodstream, leading to the erythrogenic stage, where malaria infection symptoms start appearing. In the case of P. vivax and P. ovale, the parasite may enter a dormant hypnozoite stage, significantly increasing the risk of reinfection (Markus, 2011). As the merozoites invade RBCs, they rapidly grow and develop into ring-like forms called “trophozoites” that can be identified via Giemsa staining (Giribaldi et al., 2015).

The treatment and management of malaria depend upon accurate and timely diagnosis since its symptoms can differ significantly from one person to another (Bartoloni and Zammarchi, 2012). The clinical objectives of treating uncomplicated malaria are to cure the infection as rapidly as possible and to prevent progression to severe disease. “Cure” is defined as the elimination of all parasites from the body (WHO, 2023b). Current guidelines recommend that non-falciparum malaria should be treated with a 3-day course of oral chloroquine and oral analgesics (Chiodini et al., 2007). Primaquine is considered the most effective drug to eliminate P. vivax and P. ovale, even for the dormant hypnozoites in the liver (Wångdahl et al., 2022). Artemisinin-based combination therapy is used to treat uncomplicated P. falciparum malaria infection and the artemisinin-lumefantrine combination is a drug of choice for its treatment (McIntosh et al., 1996). Severe falciparum infection is treated with intravenous (IV) drugs until the patient can be switched to oral drugs. The treatment for severe malaria in adults and children is IV artesunate (Trampuz et al., 2003). The chemical structures of some of these drugs are provided in Figure 4.

Furthermore, treatment options for pregnant women and children afflicted with malaria are different and should be used with caution to avoid undesirable side effects (Whitty, Edmonds, and Mutabingwa, 2005). In addition, severe malaria infections in pediatrics should be treated with empirical broad-spectrum antibiotics. In case of uncomplicated infection, a combination of artemether-lumefantrine can be utilized as the first line of treatment (Chiodini et al., 2007). In the first trimester of pregnancy, uncomplicated malarial infection should be treated with quinine-clindamycin combination therapy. In the second and third trimesters of pregnancy, artemether-lumefantrine treats uncomplicated P. falciparum malaria (Whitty, Edmonds, and Mutabingwa, 2005). For severe malaria, in any trimester of pregnancy, artesunate is usually preferred over quinine. Severe malarial infection by P. falciparum in pregnancy can potentially result in stillbirth or early delivery, so it's advisable to start the treatment as early as possible, under the supervision of a specialist doctor (Nunes and Scherf, 2007).

Furthermore, in patients co-infected with HIV/AIDS and uncomplicated P. falciparum malaria, artesunate + sulfadoxine-pyrimethamine is not recommended if they are being treated with co-trimoxazole. Additionally, artesunate + amodiaquine is not recommended if they are being treated with efavirenz or zidovudine (WHO, 2023a; Obeagu et al., 2024). Another critical treatment case is malaria-tuberculosis co-infection. Severe drug interaction, for example, rifampicin-induced liver injury may be worsened by amodiaquine-containing artemisinin-based combination therapy, complicating the treatment plan (Adedeji et al., 2018). Currently, there is insufficient evidence to modify the existing dosing recommendations based on mg/kg body weight. However, due to the higher risk of recrudescent malaria infections in these patients, close monitoring is advised (World Health, 2023).

Moreover, the November 2022 update to treatment recommendations for malaria includes several key points. Firstly, it suggests the use of artesunate-pyronaridine as an artemisinin-based combination therapy option for treating uncomplicated P. falciparum malaria, despite low-certainty evidence. Additionally, pregnant women diagnosed with uncomplicated P. falciparum malaria during the first trimester are advised to undergo treatment with artemether-lumefantrine, again supported by a strong recommendation despite low certainty evidence. Additionally, to prevent relapse in cases of P. vivax or P. ovale malaria in children and adults (with specific exceptions), primaquine at a dosage of 0.5 mg/kg/day for 7 days was strongly recommended. Conversely, the update advises against using primaquine at a dosage of 1.0 mg/kg/day for 7 days to prevent relapse in P. vivax or P. ovale malaria, based on a conditional recommendation and very low-certainty evidence (Organization, 2023).

In addition to antipyretics, like acetaminophen, and anti-emetics, anti-seizure medications are also advised. Importantly, generalized seizures are more common in children with P. falciparum malaria than in those with malaria caused by other species. Usually, parenteral or rectal benzodiazepines or intramuscular paraldehyde are given. However, prophylactic use of anti-convulsants has no firm empirical foundation in otherwise uncomplicated malaria and therefore is not recommended (World Health, 2023).

One of the main challenges faced by clinicians in malaria treatment is drug resistance developed by Plasmodium. P. falciparum, responsible for severe malarial infection, has developed resistance to many drugs, including chloroquine, mefloquine, and quinine (Vestergaard and Ringwald, 2007). Chloroquine is considered the most cost-effective drug for malaria management, but recent data suggests that the treatment failure rate with chloroquine is more than 70% due to rapid drug-resistance development (Vestergaard and Ringwald, 2007). Amodiaquine, an essential part of the drug combinations used for treating malaria, is also facing the same threat.

Moreover, malaria misdiagnosis is another major challenge in combatting the epidemic. Accurate use of diagnostic procedures may not only lead to early infection treatment but also help select the correct antimalarial drug regimen against a particular pathogen (Shahbodaghi and Rathjen, 2022).

Vector control is one of the bigger challenges in the fight against malaria. In addition to outdoor transmission, growing levels of insecticide resistance in targeted vectors threaten the efficacy of long-lasting insecticidal nets and indoor residual spraying. These methods reduce malaria incidence but generally have little impact on malaria prevalence. Larvicidal treatments can be useful but are not recommended for rural areas. The research needed to improve the quality and delivery of mosquito vector control (Benelli and Beier, 2017). Due to the drug-drug interaction of antimalarial drugs, caution is always needed before prescribing. When treating malaria in someone who is also taking anti-tuberculosis medications, one must be careful to prevent harmful drug interactions. This is because the anti-tuberculosis drugs, such as rifampicin and isoniazid, can cause liver damage, and this risk could be heightened by using artemisinin-based combination therapy with amodiaquine to treat malaria, potentially leading to more severe outcomes (Adedeji et al., 2018).

There is a plethora of factors behind anti-malaria drug resistance. The mechanisms of resistance to chloroquine in malaria parasites often involve mutations in the PfCRT gene, which reduce the drug accumulation within the parasite, diminishing its efficacy and facilitating parasite survival (Patel and Roy, 2021). In mosquitoes, exposure to chloroquine can lead to alterations in innate immunity, potentially affecting their ability to treat Plasmodium infections. Moreover, chloroquine disrupts normal apoptotic processes in mosquito midgut cells, potentially facilitating parasite survival and development within the mosquito host. These changes in parasite susceptibility and mosquito physiology can significantly influence malaria transmission dynamics and the proliferation of drug-resistant strains (Abrantes et al., 2008). The resistance mechanisms to mefloquine in P. falciparum involve mutations in the pfmdr1 gene, impacting drug transport and efficacy. Amplification of pfmdr1 correlates with heightened mefloquine resistance and treatment failure rates. Prolonged parasite clearance post-mefloquine treatment signifies potential resistance development. In vitro assays indicated elevated IC₅₀ values for mefloquine, indicative of decreased parasite susceptibility. Furthermore, emerging resistance to artesunate, alongside mefloquine resistance, highlights the pressing need for alternative malaria treatment approaches (Rogers et al., 2009a).

Studies regarding molecular mechanisms involved in anti-malaria drug resistance found the involvement of variation in P. vivax multidrug resistance gene 1 (PvMDR1) (Reed et al., 2000; Chaorattanakawee et al., 2017; Li et al., 2020), P. vivax chloroquine resistance transporter (PvCRT) (Sá et al., 2019), P. vivax dihydrofolate reductase-thymidylate synthase (PvDHFR-TS), dihydropteroate synthase (PvDHPS) (Hawkins et al., 2007; Auburn et al., 2018; Auburn et al., 2019), and P. vivax multidrug resistance protein 1 (PvMRP1) (Bright et al., 2013; Flannery et al., 2015) in mediating drug resistance (Buyon, Elsworth, and Duraisingh, 2021). Furthermore, chemoprevention or chemoprophylaxis strategies may also inadvertently exacerbate the resistance problem. Malaria chemoprevention interventions do not always lead to favorable outcomes; counter-intuitively, they may increase the prevalence of resistance-associated genetic mutations (Plowe, 2022).

Drugs that are effective in adults cannot be used to treat malaria in pregnancy and children. This is another area of concern as many times, the same drugs are prescribed in all age groups leading to increased risk of adverse reactions and potentially life-threatening consequences during pregnancy (Phillips-Howard and Wood, 1996). Moreover (Acosta et al., 2020), assessed the relationship among drug dose, timing, and drug resistance in the malaria model. The analysis revealed that the higher dose administration may lead to high-level resistance. In addition, altering treatment timing can also influence the risk of resistance emergence. The study concluded that identifying the “right” time and dose was crucial for maximizing clinical goals (Acosta et al., 2020). In addition, an investigation focusing on the correlation between anti-malarial market characteristics and the emergence of arteminisin revealed that there was an urgent need for tight regulation to delay the emergence and spread of arteminisin (Guissou et al., 2023).

About half of the world’s population is still at risk of contracting malaria, so making an effective malaria vaccine is the need of the hour, a goal that remains elusive for now. In 2021 the WHO approved the first malaria vaccine, RTS,S/AS01 vaccine (Mosquirix™), for widespread use. However, development continues on promising candidates such as R21, PfSPZ, and P. vivax vaccines (El-Moamly and El-Sweify, 2023).

R21/Matrix-M™ Malaria Vaccine is a product of collaboration between the University of Oxford and Novavax. By reaching 77% effectiveness in Phase 2 clinical trials, R21 demonstrated remarkable efficacy. Moreover, it is designed to be low-dose, accessible, and cost-effective, for use in children under 3 years of age (Aderinto et al., 2024). In addition to these developments, many researchers have emphasized the need for developing asexual blood-stage malaria vaccine development against Plasmodium (Takashima et al., 2024).

Thus far, two types of vaccines have been developed. One type, called subunit vaccines, like RTS,S, and R21, target a specific part of the parasite, but they have not been very effective at stimulating the immune system to protect against malaria for a long time (MacMillen et al., 2024). Another type of vaccine called whole-organism vaccines, such as Radiation Attenuated Sporozoites (RAS) exhibited better protection, but they are difficult and expensive to make since they need to be grown inside mosquitoes. Moreover, these vaccines require a series of IV doses administered over multiple clinic visits (Sissoko et al., 2022). To overcome this, researchers proposed a novel strategy called a “prime-and-trap” approach, involving using two different vaccines together. In vivo, the first vaccine (the priming dose) a single dose of a self-replicating RNA encoding full-length P. yoelii CS protein was delivered using advanced Nano carriers called LION™. The second vaccine (the trapping dose) consists of an attenuated malaria parasite, delivered as a whole-organism vaccine (WO RAS). Interestingly, an accelerated regimen, i.e., either 5-day or same-day immunization induced a strong immune response. Notably, mice vaccinated on the same day experienced a 2-day delay in the appearance of parasites in their blood and achieved 90% protection against a 3-week spz challenge. Moreover, this same-day regimen provided 70% protection against the 2-month spz challenge. This innovative approach may aid in developing vaccines that require fewer doses and provide long-lasting protection against malaria (MacMillen et al., 2024).

Furthermore, malaria transmission-blocking vaccines, which interrupt malaria transmission from one person to another, have also been tested in malaria-endemic areas of Africa. The study found that all the tested formulations were safe and well tolerated in healthy adults. Particularly, ProC6C-AlOH/Matrix-M vaccine elicited the highest levels of functional antibodies, requiring further investigation (Tiono et al., 2024).

Herbal medicines have many proven advantages over synthetic drugs, as the former is more cost-effective, has fewer side effects, and is more efficient (Mohammadi et al., 2020). Vegetal species have been used for centuries for different therapeutic purposes. Researchers from all over the world have identified numerous plant-based products that are effective in managing various diseases including malaria (Lemma et al., 2017; Hassan et al., 2021; Afzal et al., 2022; Nawaz, Ishtiaq, and Anwar, 2022). Derived from the plant named Artemisia annua, artemisinin has revolutionized the treatment of malaria (Phillipson, 1990). Similarly, various herbal medicines are derived from Cinchona species, with quinine being one of them (White, 1985). Febrifugine, another antimalarial drug, is derived from the plant Dichroea febrifuga Lour. (Farnsworth and Soejarto, 1991). Artemisinin and quinine contain bioactive compounds/phytochemicals, alkaloids and terpenoids that are effective for the treatment of malaria infection (Moyo et al., 2020). The structural formula for artemisinin, quinine, and febrifugine is shown in Figure 5. Here we describe some of the most important plants with promising anti-malarial activities.

The Himalayan region of Pakistan is renowned for its diverse herbal remedies the local communities use to treat various health problems. A study on these plants found that Asteraceae (11.9%) was the most cited vegetal family against malaria. Other plant families being used included Lamiaceae (5.9%), Solanaceae, Verbenaceae (4.7%), and Violaceae (3.5%). A study conducted by (Shah and Rahim, 2017), in the Soon Valley of Pakistan, indicated the use of more than fifty varieties for malaria treatment in the region. The researchers identified that anti-malarial properties of seven plant species were reported for the first time. These plant species included Withania coagulans (Stocks), Fagonia cretica L. (Zygophyllaceae), Carthamus oxyacanthus M.Bieb. (Asteraceae), Ehretia obtusifolia Hochst. ex A.DC. (Boraginaceae), Helianthus annuus L. (Asteraceae), Olea ferruginea (Aiton) Steud. (Oleaceae), and Vitex trifolia L. (Lamiaceae).

Another study focused on three local plants for their anti-malarial activity. The plant species analyzed included P. kurroa, C. bonducella, and A. absinthium. The investigators used cold alcohol, hot alcohol, and aqueous preparations of extracts obtained from the plants to ascertain their antimalarial activity. The study found that P. kurroa was more effective than the other two plants against malaria (Irshad, Mannan, and Mirza, 2011).

One of the strengths of this review is its emphasis on the use of natural products for malaria treatment. Natural remedies for treating malaria have several advantages over mainstream drugs. First, natural products offer a vast array of chemical structures with diverse pharmacological properties (Dias, Urban, and Roessner, 2012). This chemical diversity provides a rich source of compounds with potential anti-malarial activity, allowing for the discovery of novel drugs or drug leads. This chemical diversity also helps in delaying the emergence of drug resistance. The prevention or at least delay of drug resistance may also be helped by the fact that many natural products exhibit activity against multiple stages of the malaria parasite’s life cycle, including the blood stages (schizonts), liver stages (hypnozoites), and transmission stages (gametocytes) (Roberts et al., 2017). This multifactorial action may help prevent the development of drug resistance and improve treatment outcomes. Natural products often contain multiple bioactive compounds that can act synergistically to enhance their anti-malarial activity. This synergism may result in greater efficacy and lower risk of drug resistance compared to single-compound therapies. Most natural products exhibit anti-malarial activity with minimal toxicity to human cells, making them potentially safer alternatives to synthetic drugs (Amelo, Nagpal, and Makonnen, 2014). This is particularly important in malaria-endemic regions where access to healthcare and monitoring for adverse drug reactions may be limited. This review not only focuses on the use of natural products for treating malaria but emphasizes that combining treatment with a hybrid approach of vector control methods with rigorous hygiene measures can be an effective strategy for combating malaria. Especially, the distribution of insecticide-treated bed nets and indoor residual spraying with long-lasting insecticides can significantly reduce mosquito populations and prevent malaria transmission indoors (Hellewell et al., 2021). Targeted application of larvicides to mosquito breeding sites, such as stagnant water bodies, can prevent the development of mosquito larvae and reduce adult mosquito populations (Lardeux et al., 2002). Implementing an integrated approach that combines multiple vector control methods, tailored to local epidemiological and ecological conditions, can enhance the effectiveness and sustainability of malaria control efforts. Establishing robust surveillance systems to monitor malaria transmission dynamics, vector populations, and insecticide resistance can inform evidence-based decision-making and guide the adaptation of control strategies over time.

An important limitation of herbal medicine is the variation in the potency and effectiveness that may occur due to several factors, including geographic variations in malaria parasite strains, drug resistance patterns, and differences in local healthcare infrastructure and practices. For example, P. falciparum is the most prevalent and deadliest of the malaria parasite species, and resistance to anti-malarial drugs, such as chloroquine and sulfadoxine-pyrimethamine, has been widely reported in many regions, particularly in sub-Saharan Africa (Crider et al., 2022). National and international treatment guidelines for malaria may vary based on epidemiological data, drug resistance patterns, and healthcare resources. Treatment recommendations may be tailored to specific regions or populations to optimize treatment outcomes and minimize the risk of drug resistance. For example, ACTs are recommended as first-line treatment for uncomplicated P. falciparum malaria in most endemic regions, but the specific ACT regimen may vary based on local drug resistance patterns (Saito et al., 2023).

Another limitation of herbal treatments is the lack of standardized dosing for malaria which can have several implications, including variability in treatment efficacy, safety concerns, and challenges in comparing research findings across studies. Natural product treatments often contain complex mixtures of bioactive compounds, which may vary in concentration and composition depending on factors such as plant species, growing conditions, harvesting methods, and processing techniques (Santos-Zea et al., 2016). This variability makes it difficult to establish standardized dosing regimens across different preparations of the same natural product. Many natural products lack comprehensive pharmacokinetic data, including information on absorption, distribution, metabolism, and excretion (ADME) in humans. Without this data, it is challenging to determine optimal dosing regimens that achieve therapeutic levels of active ingredients while minimizing the risk of toxicity or suboptimal efficacy. Natural products may contain toxic compounds or interact with other medications, leading to adverse effects or drug interactions (Fugh-Berman, 2000). Without standardized dosing and rigorous safety evaluation, there is a risk of overdosing, under-dosing, or unintended adverse reactions, particularly in vulnerable populations such as children, pregnant women, or individuals with underlying health conditions.

The potential interactions of natural products such as for malaria with other medications are an important consideration, as they can impact treatment efficacy, safety, and patient outcomes, thus limiting their use (Fugh-Berman, 2000). While natural products are often perceived as safe, they contain bioactive compounds that may interact with conventional medications that may alter their pharmacokinetics or pharmacodynamics. Natural products may affect the ADME of other medications, leading to alterations in their blood levels and therapeutic effects. For example, certain natural products may inhibit or induce drug-metabolizing enzymes in the liver (e.g., cytochrome P450 enzymes), influencing the metabolism of co-administered medications and potentially leading to drug toxicity or treatment failure (Yang, Wang, and Zeng, 2002; Parvez and Rishi, 2019). Furthermore, natural products may have additive, synergistic, or antagonistic effects when combined with other medications, altering their pharmacological actions. For instance, some natural products may enhance the anticoagulant effects of blood-thinning medications or potentiate the sedative effects of central nervous system depressants. Similarly, St. John’s wort (Hypericum perforatum L.), a herbal remedy sometimes used for its antidepressant effects, could induce drug metabolizing enzymes and reduce the efficacy of medications, including certain anti-malarial drugs, oral contraceptives, and immunosuppressants (Yang, Wang, and Zeng, 2002).

Malaria remains a formidable global health challenge, causing significant morbidity and mortality, particularly in impoverished regions. Despite numerous diagnostic and medicinal breakthroughs, the Plasmodium resistance development to anti-malaria drugs will undo most of this progress. This threat has become an impetus behind the race for novel, effective, and affordable drugs and vaccines. Natural products derived from plants like A. annua, C. sanguinolenta, H. impetiginosus, P. kurroa, and A. hexapetalus are among the noteworthy sources. Interestingly, A. annua is the precursor of artemisinin, one of the most significant drugs considered a mainstay of treatment against malaria. Moreover, plants like V. lasiopus, R. prinoides, T. asiatica, C. colocynthis, and phytocompounds like isoliquiritigenin, and norcaesalpin D should be further studied for effects against drug-resistant Plasmodium species. However, while herbal medicines have advantages like cost-effectiveness and fewer side effects, they also have limitations. These limitations include variations in potency, lack of standardized dosing, and potential interactions with other medications. Therefore, either modern or herbal medicines should be used after conducting a cost-benefit analysis associated with the treatment plan. Only a balanced approach can have an effectual impact. In addition, an emphasis on early detection, accurate diagnosis, and integrated efforts for disease prevention is also crucial. Additionally, implementing stringent hygiene measures and promoting community awareness will also contribute to reducing the burden of malaria in endemic areas.